Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung SDI (006400/KS) – SK Securities | Prominent Base Effects · Conservative CapEx Management · Compelling Valuation / 2026-02-03 Research
  • [Research] Samsung Biologics (207940) – Shinhan Securities | Rockville Revenue Recognition · Guidance Revision Potential · Songdo Plant 6 Groundbreaking / 2026-04-23 Research
  • [Research] LIG D&A (079550) – Shinhan Securities | 4Q25 One-off Shock · KRW 26.2T Backlog · Long-term Structural Growth / 2026-02-20 Research
  • [Research] Samsung Biologics (207940) – Kiwoom Securities | Plant 6 Groundbreaking Visibility · Labor Negotiation · Rockville Revenue Recognition / 2026-04-02 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Post-Spinoff Profitability · Record KRW 6.8T Orders · Plant 6 Groundbreaking Visibility / 2026-01-07 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | Dual Up-cycle · Large-Scale CapEx · Target Price Upgrade / 2026-07-08 Research
  • [Research] Hanwha Ocean (042660) – DS Investment & Securities | Low-Price Mix Reduction · Merchant Margin Step-Up · MASGA & Defense Pipeline / 2026-04-28 Research
  • [Research] Samsung SDI (006400) – IBK Securities | Fully Booked North America ESS · Hungarian Utilization Recovery · 4Q26 Turnaround / 2026-04-29 Research

[Research] SK hynix (000660 / SKHY) – iM Securities | Memory ASP · Server Demand · Earnings Upgrades / 2026-03-31

Posted on March 31, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : iM Securities

Investment Rating : Buy (Maintain)

Target Price : 1,500,000 KRW (Upgraded)

Core Momentum : Sharp DRAM and NAND ASP increases are driving substantial earnings upgrades, while sustained server shipment growth and rising memory content supported by Big Tech Capex are critical to extending demand momentum beyond the first half.

📊 1. [Valuation & Key Financial Metrics]

  • Target Price / Investment Rating: 1,500,000 KRW / Buy (Maintain)
  • Current Price (as of March 31, 2026): 807,000 KRW (Upside potential: 85.9%)
  • Capital / Shares Outstanding / Market Capitalization: 3,658 billion KRW / 712.7 million shares / 622,189 billion KRW
  • Foreign Ownership / 52-Week Price Range: 53.1% / 164,800 ~ 1,099,000 KRW
  • Key Financial Metrics (2025 / 2026E / 2027E / 2028E):
    • Revenue: 97,147 billion KRW / 314,416 billion KRW / 289,263 billion KRW / 332,653 billion KRW
    • Operating Profit: 47,206 billion KRW / 233,545 billion KRW / 185,638 billion KRW / 213,643 billion KRW
    • Net Income: 42,919 billion KRW / 187,799 billion KRW / 151,166 billion KRW / 175,360 billion KRW
    • EPS: 58,955 KRW / 263,502 KRW / 212,102 KRW / 246,049 KRW
    • BPS: 165,544 KRW / 429,684 KRW / 638,977 KRW / 882,217 KRW
    • PER: 11.0x / 3.3x / 4.1x / 3.5x
    • PBR: 3.9x / 2.0x / 1.4x / 1.0x
    • ROE: 44.2% / 88.0% / 39.7% / 32.3%
    • EV/EBITDA: 7.6x / 1.9x / 1.6x / 0.7x

🚀 2. [Market Opportunities & Business Outlook]

  • Upward Revisions to Earnings Projections (2Q26 & FY26): Operating profit forecasts for the second quarter and full year have been lifted to 60.6 trillion KRW and 233.5 trillion KRW, respectively, reflecting upward adjustments to DRAM and NAND ASP growth expectations. Despite mounting pricing levels, customers exhibit unwavering appetite to secure memory supplies.
  • 1Q26 Performance Preview: Revenue and operating profit for the first quarter are estimated at 56.8 trillion KRW and 39.4 trillion KRW, representing quarter-on-quarter growth of 73% and 105%. Factoring in provisions for employee bonuses, actual operating profit likely reaches 43.3 trillion KRW. Exceptional performance stems from sharp 71% and 80% surges in DRAM and NAND ASPs alongside favorable USD-KRW exchange rate movements.
  • Demand Outlook Beyond 2Q26 and Capex Variables: To offset headwinds from sluggish PC and smartphone demand from 2Q26 onwards, a rapid increase in server shipments and memory content per box is essential, with the continued upward revision of Big Tech Capex growth acting as a critical variable supporting this trend.
  • Spot Pricing and Supply Dynamics: While mild softness in spot prices is unlikely to trigger a severe downturn, any accelerated pullback could increase memory BOM cost pressures across the industry, requiring close tracking of near-term spot price behavior.
  • Valuation and Geopolitical Risks: The stock currently trades below 2x its FY26 BPS, with valuation multiples under pressure due to geopolitical tensions. Assuming an ADR listing in the second half allows multiples to approach prior peak levels, the 1.5 million KRW target price remains achievable. However, prolonged geopolitical conflicts could weigh on tech investments and industry conditions, warranting potential multiple contractions.

📝 Editor’s Comment (Perspective)

The analyst evaluates that despite valuation contraction concerns driven by geopolitical uncertainties, sharp ASP expansion in DRAM and NAND together with currency tailwinds have propelled substantial upward revisions to quarterly and annual earnings outlooks. Furthermore, the analysis highlights that sustained growth in server shipments and memory capacity alongside the ongoing upward revision of Big Tech Capex growth rates serve as vital verification variables to absorb sluggishness in PC and smartphone sectors post-2Q26.

To determine whether this investment thesis is unfolding as projected, key items to monitor include Q1 profit provisions, the trajectory of DRAM and NAND ASPs, spot price stability, and how Big Tech Capex trends and geopolitical developments impact broader capital expenditures and industry trends. These developments can be tracked through upcoming quarterly and annual earnings releases, official corporate IR materials, and regulatory disclosures via DART/KRX.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] Samsung SDI (006400) – Kyobo Securities | 1Q Trough Passing · ESS Utilization Gains · Humanoid Client Expansion / 2026-03-30
Next Post: [Research] LigaChem Biosciences (141080) – Kyobo Securities | Pipeline Clinical Progress · IND Filings · Tech Transfer / 2026-04-01

Related Posts

  • [Research] LigaChem Biosciences (141080) – Kyobo Securities | Pipeline Clinical Progress · IND Filings · Tech Transfer / 2026-04-01 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | AI Infrastructure · LTA · HBM Demand / 2026-06-09 Research
  • [Research] SK hynix (000660 / SKHY) – Hana | Commodity DRAM Pricing · LTA · Multiple Expansion / 2026-06-26 Research
  • [Research] Samsung Biologics (207940) – Mirae Asset | Plant 5 Ramp-up · CDMO Expansion · Earnings Forecast / 2026-07-27 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Supply Discipline · LTA · Shareholder Returns / 2026-07-30 Research
  • [Research] Samsung Biologics (207940) – Daishin Securities | 4Q Earnings Recovery · New Plant Ramp-up · Peptide Expansion / 2026-07-24 Research
  • [Research] LIG D&A (079550) – Yuanta Securities | Cheongung-II Demand Surge · OPM Guidance Upgrade · Middle East Overlap / 2026-08-07 Research
  • [Research] ABL Bio (298380) – DS Investment & Securities | ABL001 Data Readout · ABL111 Phase 3 · Grabody B Expansion / 2026-04-07 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Legacy Memory Pricing · LTA · ADR / 2026-02-23 Research
  • [Research] SK hynix (000660 / SKHY) – DS Investment | Commodity DRAM · ASP Resilience · Earnings Growth / 2026-07-29 Research
  • [Research] ABL Bio (298380) – Yuanta Securities | Givastomig Efficacy · Bispecific ADC · Platform Valuation / 2026-01-29 Research
  • [IR] SK hynix (000660 / SKHY) – Q1 2024 Earnings Presentation / 2024-04-25 IR Room
  • [Research] Samsung Electro-Mechanics (009150) – Kiwoom Securities | Non-Commodity Shift · Structural Shortage · Price Cycle / 2026-07-31 Research
  • [Research] SK hynix (000660 / SKHY) – Hanwha | LTA · HBM · Valuation Re-rating / 2026-06-22 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme